Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer

Journal of Translational Medicine

Meeting Report

Sana Intidhar Labidi-Galy¹  Petros Tsantoulis¹  Alberto Ballestrero²  Valerio Gaetano Vellone²  Gabriele Zoppoli²  Yves Pommier³  Junko Murai³  Elisabetta Leo⁴  Davide Bedognetti⁵  Paola Franceschelli⁶  Domenico Ferraioli⁷ 

[1] Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland;Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Martino IST-Istituto Nazionale Tumori, Genoa, Italy;Università degli Studi di Genova, Viale Benedetto XV, 6, 16132, Genoa, Italy;Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;Oncology, Innovative Medicine Early Development, AstraZeneca, Cambridge, UK;Tumor Biology Immunology and Therapy Branch, Sidra Medical and Research Center, Doah, Qatar;Università degli Studi di Genova, Viale Benedetto XV, 6, 16132, Genoa, Italy;Università degli Studi di Genova, Viale Benedetto XV, 6, 16132, Genoa, Italy;Centre de Lutte contre le Cancer Léon Bérard, Lyon, France;

关键词: SLFN11;    Biomarker;    Immune system;    DNA damage repair;    Chemotherapy;    Prognosis;    Prediction;    Ovarian cancer;    Colorectal cancer;    Breast cancer;   

DOI  :  10.1186/s12967-017-1296-3

 received in 2017-07-17, accepted in 2017-09-12,  发布年份 2017

来源: Springer

【 摘 要 】

SLFN11 is a recently discovered protein with a putative DNA/RNA helicase function. First identified in association with the maturation of thymocytes, SLFN11 was later causally associated, by two independent groups, with the resistance to DNA damaging agents such as topoisomerase I and II inhibitors, platinum compounds, and other alkylators, making it an attractive molecule for biomarker development. Later, SLFN11 was linked to antiviral response in human cells and interferon production, establishing a potential bond between immunity and chemotherapy. Recently, we demonstrated the potential role of SLN11 as a biomarker to predict sensitivity to the carboplatin/taxol combination in ovarian cancer. The present manuscript reports on the first international monothematic workshop on SLFN11. Several researchers from around the world, directly and actively involved in the discovery, functional characterization, and study of SLFN11 for its biomarker and medicinal properties gathered to share their views on the current knowledge advances concerning SLFN11. The aim of the manuscript is to summarize the authors’ interventions and the main take-home messages resulting from the workshop.

【 授权许可】

CC BY   
© The Author(s) 2017